Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Merck
Merck
Merck Says Emerging Market Drugs to Generate 25% of 2013 Revenue
Bloomberg
Tue, 01/11/11 - 12:43 pm
Merck
emerging markets
Merck Reports FDA Acceptance of NDA for Janumet
Bloomberg
Tue, 01/11/11 - 12:41 pm
Merck
FDA
Janumet
NDA
diabetes
Charge This! A Fired Merck Sales Rep & A Credit Card
Pharmalot
Tue, 01/11/11 - 12:29 pm
Merck
drug reps
Will Drug Repurposing Mean Healthy Profits?
Seeking Alpha
Mon, 01/10/11 - 07:28 pm
drug repurposing
Celgene
Merck
Pfizer
A Biotech Roller Coaster
Motley Fool
Sat, 01/8/11 - 11:57 am
Lexicon Pharmaceuticals
diabetes
LX4211
Merck
obesity
Amylin
Januvia
Onglyza
Bristol-Myers Squibb
AstraZeneca
Could Merck Be the Top Dow Stock in 2011?
Seeking Alpha
Sat, 01/8/11 - 11:54 am
Merck
investors
Biotech Stock Mailbag: Best Stocks to Watch in '11
TheStreet.com
Fri, 01/7/11 - 07:21 am
Oncothyreon
Xoma
Amarin
Opexa
Human Genome
Seattle Genetics
Vertex Pharmaceuticals
Merck
Dendreon
Biogen Idec
Amgen
Pharmasset
Merck CEO Frazier Vows ‘Tough’ Use of Spending for Innovation
Bloomberg
Thu, 01/6/11 - 12:40 pm
Merck
Pharma CEOs
Kenneth Frazier
innovation
Merck Beats Vertex to FDA Hep C Filing
TheStreet.com
Thu, 01/6/11 - 12:38 pm
Merck
Vertex Pharmaceuticals
FDA
hepatitis C
The World's Most-Watched Pharma
Motley Fool
Thu, 01/6/11 - 08:01 am
JNJ
Pfizer
Abbott Laboratories
Merck
Teva Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Merck Ends Drug Research Pact With Ranbaxy, Economic Times Says
Bloomberg
Thu, 01/6/11 - 07:41 am
Merck
Ranbaxy
A Pregnant Pause Over A Merck Contraceptive
Pharmalot
Wed, 01/5/11 - 12:12 pm
Merck
Implanon
UK
contraceptives
4-Star Stocks Poised to Pop: Merck
Motley Fool
Mon, 01/3/11 - 12:08 pm
Merck
This NICE Deal Could Foreshadow 2011
Motley Fool
Fri, 12/31/10 - 10:55 am
NICE
GSK
Pfizer
Human Genome Sciences
Bristol-Myers Squibb
Merck
AstraZeneca
value-based pricing
2011 Drugmaker M&A Targets
Motley Fool
Fri, 12/31/10 - 10:00 am
M&A
Pfizer
Merck
Genzyme
Sanofi
JNJ
Crucell
ONYX Pharmaceuticals
Bayer
Momenta
Novartis
GSK
Human Genome Sciences
Vertex Pharmaceuticals
MannKind
Vivus
Savient
A Look At The Drug Makers Of 2010
Investopedia
Fri, 12/31/10 - 09:56 am
JNJ
Merck
Novartis
Pfizer
Roche
The Most Promising Dividends in Pharmaceuticals
Motley Fool
Wed, 12/29/10 - 11:48 am
dividends
Eli Lilly
GSK
Bristol-Myers Squibb
Pfizer
Merck
Abbott Laboratories
JNJ
Merdian
Sanofi
Novartis
AstraZeneca
Teva Pharmaceuticals
Novo Nordisk
Merck’s Cholesterol Drug May Become Catalyst for Future Growth
Seeking Alpha
Wed, 12/29/10 - 10:42 am
Merck
Anacetrapib
cholesterol
3 Catalysts That Could Push DepoMed Share Price Higher
Seeking Alpha
Tue, 12/28/10 - 11:00 am
Depomed
Merck
Glumetza
Merck's Gardasil wins approval for anal cancer
Reuters
Thu, 12/23/10 - 08:27 am
Merck
HPV
anal cancer
Gardasil
Pages
« first
‹ previous
…
169
170
171
172
173
174
175
176
177
…
next ›
last »